{"type": "financial", "level": "location", "length": "128k", "file": "2U, Inc..txt", "context_order": 0, "question": "How many clients does 2U, Inc. have as of December 31, 2023?", "answer": "2U, Inc. has more than 260 clients as of December 31, 2023."}
{"type": "financial", "level": "location", "length": "128k", "file": "2U, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, how many executive-sponsored business resource networks (BRNs) did the company have?", "answer": "The company had 9 executive-sponsored business resource networks."}
{"type": "financial", "level": "location", "length": "128k", "file": "2U, Inc..txt", "context_order": 2, "question": "What was the net carrying value of the edX trade name as of December 31, 2023?", "answer": "$76.7 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "2U, Inc..txt", "context_order": 3, "question": "What is the required minimum Recurring Revenues as per the Second Amended Credit Agreement?", "answer": "$900 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "2U, Inc..txt", "context_order": 4, "question": "What is the term expiration year for the lease of 2U, Inc.'s headquarters in Lanham, Maryland?", "answer": "2028."}
{"type": "financial", "level": "location", "length": "128k", "file": "2U, Inc..txt", "context_order": 6, "question": "What was the translation adjustment loss for foreign currency for the year ended December 31, 2023?", "answer": "The foreign currency translation adjustment loss was $5.7 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "2U, Inc..txt", "context_order": 7, "question": "What kind of liabilities does the Company recognize related to uncertain tax positions?", "answer": "The Company records a liability for unrecognized tax benefits resulting from uncertain tax positions."}
{"type": "financial", "level": "location", "length": "128k", "file": "2U, Inc..txt", "context_order": 8, "question": "What is the total future minimum payment that 2U, Inc. is obligated to make to university clients as of December 31, 2023?", "answer": "$17,569,000."}
{"type": "financial", "level": "location", "length": "128k", "file": "2U, Inc..txt", "context_order": 9, "question": "How much stock-based compensation expense was recognized in 2022?", "answer": "$80.2 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "3D Systems Corp..txt", "context_order": 0, "question": "What is the name of the wholly-owned biotech company formed by 3D Systems in 2022?", "answer": "Systemic Bio."}
{"type": "financial", "level": "location", "length": "128k", "file": "3D Systems Corp..txt", "context_order": 1, "question": "Who is the company's Executive Vice President and Chief Technology Officer for Regenerative Medicine?", "answer": "Charles W. Hull."}
{"type": "financial", "level": "location", "length": "128k", "file": "3D Systems Corp..txt", "context_order": 2, "question": "How many shares of the company's common stock were surrendered for tax withholding obligations in December 2022?", "answer": "67,575 shares of common stock were surrendered for tax withholding obligations in December 2022."}
{"type": "financial", "level": "location", "length": "128k", "file": "3D Systems Corp..txt", "context_order": 3, "question": "What was the total revenue for the year ended December 31, 2022?", "answer": "$538.0 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "3D Systems Corp..txt", "context_order": 4, "question": "What percentage of 3D Systems' net sales in 2022 was attributable to entities with functional currencies other than the U.S. dollar?", "answer": "Approximately 39.4% of net sales."}
{"type": "financial", "level": "location", "length": "128k", "file": "3D Systems Corp..txt", "context_order": 5, "question": "What was the net loss income attributable to 3D Systems Corporation for the year ended December 31, 2022?", "answer": "$(122,711)"}
{"type": "financial", "level": "location", "length": "128k", "file": "3D Systems Corp..txt", "context_order": 6, "question": "What was the net income attributable to 3D Systems Corp. for the year ended December 31, 2021?", "answer": "$322,052."}
{"type": "financial", "level": "location", "length": "128k", "file": "3D Systems Corp..txt", "context_order": 7, "question": "What was the fair value of cash acquired with the Volumetric acquisition?", "answer": "$389."}
{"type": "financial", "level": "location", "length": "128k", "file": "3D Systems Corp..txt", "context_order": 8, "question": "What was the total revenue for 3D Systems Corporation for the year ended December 31, 2022?", "answer": "$538,031,000."}
{"type": "financial", "level": "location", "length": "128k", "file": "3D Systems Corp..txt", "context_order": 9, "question": "How many shares of restricted stock that vest under specified Company performance measures were included in the outstanding balance as of December 31, 2022?", "answer": "1,215 shares of restricted stock."}
{"type": "financial", "level": "location", "length": "128k", "file": "Block, Inc..txt", "context_order": 0, "question": "What date did Square, Inc. change its corporate name to Block, Inc.?", "answer": "On December 1, 2021, Square, Inc. changed its corporate name to Block, Inc."}
{"type": "financial", "level": "location", "length": "128k", "file": "Block, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, how many full-time employees did the company have worldwide?", "answer": "The company had 12,985 full-time employees worldwide."}
{"type": "financial", "level": "location", "length": "128k", "file": "Block, Inc..txt", "context_order": 2, "question": "What portion of Bitcoin does the company hold in offline and air-gapped cold storage?", "answer": "The vast majority of bitcoin we hold for ourselves and our customers is held in offline and air-gapped cold storage."}
{"type": "financial", "level": "location", "length": "128k", "file": "Block, Inc..txt", "context_order": 3, "question": "As of December 31, 2023, what was the outstanding aggregate principal amount of 2025 Convertible Notes?", "answer": "$1.0 billion."}
{"type": "financial", "level": "location", "length": "128k", "file": "Block, Inc..txt", "context_order": 4, "question": "As of February 16, 2024, how many holders of record were there for Block, Inc.'s Class A common stock?", "answer": "As of February 16, 2024, there were 637 holders of record for Block, Inc.'s Class A common stock."}
{"type": "financial", "level": "location", "length": "128k", "file": "Block, Inc..txt", "context_order": 5, "question": "What was the increase in net cash provided by investing activities for the year ended December 31, 2023?", "answer": "Net cash provided by investing activities increased by $683.2 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Block, Inc..txt", "context_order": 6, "question": "What was Block, Inc.'s total revenue for the year ended December 31, 2023?", "answer": "$21,915,623,000."}
{"type": "financial", "level": "location", "length": "128k", "file": "Block, Inc..txt", "context_order": 7, "question": "What was the total net revenue for the year ended December 31, 2023?", "answer": "$21,915,623,000."}
{"type": "financial", "level": "location", "length": "128k", "file": "Block, Inc..txt", "context_order": 8, "question": "What was the credit provision for consumer receivables acquired from Afterpay from January 31, 2022, to December 31, 2022?", "answer": "$203,670,000."}
{"type": "financial", "level": "location", "length": "128k", "file": "Block, Inc..txt", "context_order": 9, "question": "What was the total amount of shares repurchased by the Company during the year ended December 31, 2023?", "answer": "2.5 million shares of Class A common stock."}
{"type": "financial", "level": "location", "length": "128k", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 0, "question": "What was C.H. Robinson Worldwide, Inc.'s total consolidated revenue for the year ended December 31, 2023?", "answer": "C.H. Robinson Worldwide, Inc.'s total consolidated revenue was $17.6 billion in 2023."}
{"type": "financial", "level": "location", "length": "128k", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 1, "question": "What was the engagement score from the 2023 survey?", "answer": "77 percent."}
{"type": "financial", "level": "location", "length": "128k", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 2, "question": "When did Michael P. Zechmeister plan to retire from his position as Chief Financial Officer?", "answer": "No later than May 31, 2024."}
{"type": "financial", "level": "location", "length": "128k", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 3, "question": "Where is the corporate headquarters of C.H. Robinson Worldwide, Inc. located?", "answer": "The corporate headquarters is in Eden Prairie, Minnesota."}
{"type": "financial", "level": "location", "length": "128k", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 4, "question": "What was the diluted net income per share for the twelve months ended December 31, 2023?", "answer": "$2.72."}
{"type": "financial", "level": "location", "length": "128k", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 5, "question": "What was the effect of exchange rates on cash and cash equivalents for the year ended December 31, 2023?", "answer": "A decrease of $3,284,000."}
{"type": "financial", "level": "location", "length": "128k", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 6, "question": "What was the opinion expressed by the auditing firm regarding C.H. Robinson Worldwide, Inc.'s internal control over financial reporting as of December 31, 2023?", "answer": "The auditing firm expressed that C.H. Robinson Worldwide, Inc. maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023."}
{"type": "financial", "level": "location", "length": "128k", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 7, "question": "What was the carrying value of total debt as of December 31, 2023?", "answer": "$1,580,487 thousand."}
{"type": "financial", "level": "location", "length": "128k", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 8, "question": "What was the total value of shares repurchased by the company in 2023?", "answer": "$62,778 thousand."}
{"type": "financial", "level": "location", "length": "128k", "file": "C.H. ROBINSON WORLDWIDE, INC..txt", "context_order": 9, "question": "What was the amount of total restructuring charges recognized for the 2023 South American Restructuring Program?", "answer": "$21.2 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 0, "question": "What was the total revenue for Exact Sciences Corporation for the year ended December 31, 2023?", "answer": "$2.50 billion."}
{"type": "financial", "level": "location", "length": "128k", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 1, "question": "As of December 31, 2023, how many issued patents does the company own in the U.S.?", "answer": "As of December 31, 2023, the company owns 208 issued patents in the U.S."}
{"type": "financial", "level": "location", "length": "128k", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 2, "question": "What location houses both the headquarters and one of the test facilities?", "answer": "Madison, Wisconsin houses both the headquarters and one of the test facilities."}
{"type": "financial", "level": "location", "length": "128k", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 3, "question": "What was the settlement amount paid by the company in September 2023 due to a civil investigative demand related to Genomic Health's Medicare billing compliance?", "answer": "The settlement amount paid in September 2023 was $32.5 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 4, "question": "As of December 31, 2023, what is the total indebtedness of the company?", "answer": "The total indebtedness is $2.39 billion."}
{"type": "financial", "level": "location", "length": "128k", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 5, "question": "What is the projected fiscal year range for the Thrive milestone payments related to FDA approval and CMS coverage?", "answer": "The projected fiscal year of payment range is from 2028 to 2030."}
{"type": "financial", "level": "location", "length": "128k", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 6, "question": "What was the net loss for Exact Sciences Corporation for the year ended December 31, 2023?", "answer": "$204,149,000."}
{"type": "financial", "level": "location", "length": "128k", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 7, "question": "What was the total revenue of EXACT Sciences Corporation for the year ended December 31, 2023?", "answer": "$2,499,766,000."}
{"type": "financial", "level": "location", "length": "128k", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 8, "question": "When will the license agreement with Mayo expire?", "answer": "The license agreement will remain in effect until the last of the licensed patents expires in 2039."}
{"type": "financial", "level": "location", "length": "128k", "file": "EXACT SCIENCES CORPORATION.txt", "context_order": 9, "question": "What was the acquisition date fair value of the consideration transferred for the Ashion Acquisition?", "answer": "The acquisition date fair value of the consideration transferred for Ashion was approximately $110.0 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Esperion Therapeutics Inc.txt", "context_order": 0, "question": "What was the total collaboration revenue recognized during the year ended December 31, 2023?", "answer": "$38.0 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Esperion Therapeutics Inc.txt", "context_order": 1, "question": "What is the expiration date of U.S. Patent No. 7,335,799 covering bempedoic acid, including patent term adjustment?", "answer": "December 2025."}
{"type": "financial", "level": "location", "length": "128k", "file": "Esperion Therapeutics Inc.txt", "context_order": 2, "question": "How many full-time employees did the company have as of December 31, 2023?", "answer": "The company had 240 full-time employees as of December 31, 2023."}
{"type": "financial", "level": "location", "length": "128k", "file": "Esperion Therapeutics Inc.txt", "context_order": 3, "question": "Which regulatory authorities have granted approval for the company’s leading product candidates as an adjunct to diet and statin therapy for the treatment of primary hyperlipidemia?", "answer": "The FDA, the EC, and Swissmedic."}
{"type": "financial", "level": "location", "length": "128k", "file": "Esperion Therapeutics Inc.txt", "context_order": 4, "question": "What is the annual aggregate coverage limit of the product liability insurance for clinical studies?", "answer": "$10.0 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Esperion Therapeutics Inc.txt", "context_order": 5, "question": "What is the senior security interest granted to Oberland under the RIPA?", "answer": "A senior security interest in the company's assets."}
{"type": "financial", "level": "location", "length": "128k", "file": "Esperion Therapeutics Inc.txt", "context_order": 6, "question": "What was the net loss for Esperion Therapeutics, Inc. for the year ended December 31, 2023?", "answer": "$209.2 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Esperion Therapeutics Inc.txt", "context_order": 7, "question": "What were the net proceeds from the Registered Direct Offering for the year ended December 31, 2023?", "answer": "Approximately $51.3 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Esperion Therapeutics Inc.txt", "context_order": 8, "question": "What was the net cash provided by investing activities for the year ended December 31, 2023?", "answer": "$42,500 thousand."}
{"type": "financial", "level": "location", "length": "128k", "file": "Esperion Therapeutics Inc.txt", "context_order": 9, "question": "What is the effective annual imputed interest rate on the revenue interest liability as of December 31, 2023?", "answer": "17.6%."}
{"type": "financial", "level": "location", "length": "128k", "file": "MediaAlpha, Inc..txt", "context_order": 1, "question": "What percentage of the company's revenue for the year ended December 31, 2023, came from its insurance verticals?", "answer": "96.6% of the revenue."}
{"type": "financial", "level": "location", "length": "128k", "file": "MediaAlpha, Inc..txt", "context_order": 2, "question": "What was the aggregate principal amount outstanding under the 2021 Term Loan Facility as of December 31, 2023?", "answer": "$171.0 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "MediaAlpha, Inc..txt", "context_order": 3, "question": "Which cloud infrastructure provider does the company rely on for hosting its platform?", "answer": "The company relies on Amazon Web Services (AWS) for hosting its platform."}
{"type": "financial", "level": "location", "length": "128k", "file": "MediaAlpha, Inc..txt", "context_order": 4, "question": "What were the low and high closing sales prices of Class A common stock from the IPO through December 31, 2023?", "answer": "The low and high closing sales prices of Class A common stock ranged from $5.36 to $64.11 per share."}
{"type": "financial", "level": "location", "length": "128k", "file": "MediaAlpha, Inc..txt", "context_order": 5, "question": "What was the revenue generated by the company for the year ended December 31, 2023?", "answer": "$388.1 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "MediaAlpha, Inc..txt", "context_order": 6, "question": "What was the total Transaction Value for the year ended December 31, 2023?", "answer": "$593,438 thousand."}
{"type": "financial", "level": "location", "length": "128k", "file": "MediaAlpha, Inc..txt", "context_order": 7, "question": "What is the total amount of goodwill reported as of December 31, 2023?", "answer": "$47,739."}
{"type": "financial", "level": "location", "length": "128k", "file": "MediaAlpha, Inc..txt", "context_order": 8, "question": "What was the total revenue for MediaAlpha, Inc. for the year ended December 31, 2023?", "answer": "$388,149,000."}
{"type": "financial", "level": "location", "length": "128k", "file": "MediaAlpha, Inc..txt", "context_order": 9, "question": "What was the balance of operating lease liabilities classified as non-current as of December 31, 2023?", "answer": "$1,650 thousand."}
{"type": "financial", "level": "location", "length": "128k", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 0, "question": "What is the primary endpoint that the Phase 2b clinical trial of MM120 met for the treatment of generalized anxiety disorder?", "answer": "Statistically significant and clinically meaningful dose-dependent improvements on the Hamilton Anxiety (HAM-A) rating scale compared to placebo at Week 4."}
{"type": "financial", "level": "location", "length": "128k", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 1, "question": "When did the company enter into a collaboration with Dr. Matthias Liechti's lab at UHB?", "answer": "On April 1, 2020."}
{"type": "financial", "level": "location", "length": "128k", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 2, "question": "What does the Pediatric Research Equity Act require certain NDAs to contain?", "answer": "Data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations."}
{"type": "financial", "level": "location", "length": "128k", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 3, "question": "What is the maximum timeframe for the evaluation of a marketing authorization application in the EU?", "answer": "The maximum timeframe is 210 days, not including clock stops during which applicants respond to questions from the competent authority."}
{"type": "financial", "level": "location", "length": "128k", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 4, "question": "As of December 31, 2023, how much cash and cash equivalents did the company have?", "answer": "$99.7 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 5, "question": "What was the amount available for issuance under the shelf registration statement at December 31, 2023?", "answer": "$99.8 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 6, "question": "What may cause material adverse changes in the final clinical trial data?", "answer": "Material adverse changes in the final data compared to the interim data could significantly harm our business prospects."}
{"type": "financial", "level": "location", "length": "128k", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 7, "question": "What impact does the failure to gain market access and acceptance of product candidates have on the company's revenue?", "answer": "It will have a material adverse impact on the ability to generate revenue to provide a satisfactory, or any, return on investments."}
{"type": "financial", "level": "location", "length": "128k", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 8, "question": "What happens if the pricing of our product candidates is set at unsatisfactory levels or if reimbursement is unavailable or limited?", "answer": "Our revenue from sales and the potential profitability of our product candidates in those countries would be negatively affected."}
{"type": "financial", "level": "location", "length": "128k", "file": "Mind Medicine (MindMed) Inc..txt", "context_order": 9, "question": "As of December 31, 2023, how many full-time and part-time employees did the company have?", "answer": "57 full-time and part-time employees."}
{"type": "financial", "level": "location", "length": "128k", "file": "NVIDIA Corporation.txt", "context_order": 0, "question": "How many business segments does NVIDIA Corporation report its business results in?", "answer": "NVIDIA Corporation reports its business results in two segments."}
{"type": "financial", "level": "location", "length": "128k", "file": "NVIDIA Corporation.txt", "context_order": 1, "question": "As of the end of fiscal year 2024, how many employees were engaged in research and development at NVIDIA?", "answer": "22,200 employees were engaged in research and development."}
{"type": "financial", "level": "location", "length": "128k", "file": "NVIDIA Corporation.txt", "context_order": 2, "question": "What percentage of NVIDIA's revenue in fiscal year 2024 was generated from sales outside of the United States?", "answer": "56% of NVIDIA's revenue was generated from sales outside of the United States in fiscal year 2024."}
{"type": "financial", "level": "location", "length": "128k", "file": "NVIDIA Corporation.txt", "context_order": 3, "question": "How many employees are in the region impacted by the geopolitical conflict in and around Israel?", "answer": "There are approximately 3,700 employees in the region."}
{"type": "financial", "level": "location", "length": "128k", "file": "NVIDIA Corporation.txt", "context_order": 4, "question": "What is the symbol under which NVIDIA's common stock is traded?", "answer": "NVIDIA's common stock is traded under the symbol NVDA."}
{"type": "financial", "level": "location", "length": "128k", "file": "NVIDIA Corporation.txt", "context_order": 5, "question": "What was NVIDIA's total revenue for fiscal year 2024?", "answer": "$60.9 billion."}
{"type": "financial", "level": "location", "length": "128k", "file": "NVIDIA Corporation.txt", "context_order": 6, "question": "What was the amount of acquisition termination cost related to the Arm transaction recorded in fiscal year 2023?", "answer": "$1.4 billion."}
{"type": "financial", "level": "location", "length": "128k", "file": "NVIDIA Corporation.txt", "context_order": 7, "question": "What was the total shareholders' equity of NVIDIA Corporation as of January 28, 2024?", "answer": "$42,978 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "NVIDIA Corporation.txt", "context_order": 8, "question": "What is the expected weighted average period over which the unearned stock-based compensation expense will be recognized for RSUs, PSUs, and market-based PSUs as of January 28, 2024?", "answer": "2.5 years."}
{"type": "financial", "level": "location", "length": "128k", "file": "NVIDIA Corporation.txt", "context_order": 9, "question": "What was NVIDIA's total revenue for the year ended January 28, 2024?", "answer": "$60,922 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 0, "question": "What is the page number for the 'Signature' section in this financial statement?", "answer": "150"}
{"type": "financial", "level": "location", "length": "128k", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 1, "question": "What is the expected expiration year of U.S. Patent No. 9,265,740 related to omadacycline?", "answer": "The method of use patent (U.S. 9,265,740) is expected to be extended until October 2030."}
{"type": "financial", "level": "location", "length": "128k", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 2, "question": "What is the primary business segment for Paratek Pharmaceuticals, Inc. as defined by generally accepted accounting principles?", "answer": "Paratek Pharmaceuticals, Inc. operates its business as a single segment."}
{"type": "financial", "level": "location", "length": "128k", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 3, "question": "What is the withdrawal quantity of NUZYRA's second procurement accepted by BARDA in December 2022?", "answer": "2,500 treatment courses of NUZYRA."}
{"type": "financial", "level": "location", "length": "128k", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 4, "question": "What is the annual interest rate for the 4.75% Convertible Senior Subordinated Notes issued in April 2018?", "answer": "The Notes bear cash interest at the annual rate of 4.75%."}
{"type": "financial", "level": "location", "length": "128k", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 5, "question": "What was the net loss for the year ended December 31, 2022?", "answer": "$63.6 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 6, "question": "What was the net loss for Paratek Pharmaceuticals, Inc. for the year ended December 31, 2022?", "answer": "$63.6 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 7, "question": "What was Paratek Pharmaceuticals, Inc.'s accumulated deficit through December 31, 2022?", "answer": "$930.4 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 8, "question": "What was the Company's total cash, cash equivalents and restricted cash as of December 31, 2022?", "answer": "$34.4 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Paratek Pharmaceuticals Inc.txt", "context_order": 9, "question": "What was the total coupon interest expense recognized by the Company for the R-Bridge Loan Agreement in the year ended December 31, 2022?", "answer": "$4.4 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Tesla, Inc..txt", "context_order": 0, "question": "Which two reportable segments does Tesla, Inc. operate?", "answer": "Automotive and energy generation and storage."}
{"type": "financial", "level": "location", "length": "128k", "file": "Tesla, Inc..txt", "context_order": 1, "question": "As of December 31, 2023, what was Tesla's worldwide employee headcount?", "answer": "140,473."}
{"type": "financial", "level": "location", "length": "128k", "file": "Tesla, Inc..txt", "context_order": 2, "question": "As of December 31, 2023, how much aggregate principal amount of indebtedness did Tesla and its subsidiaries have outstanding?", "answer": "$4.68 billion."}
{"type": "financial", "level": "location", "length": "128k", "file": "Tesla, Inc..txt", "context_order": 3, "question": "What was the intra-day trading high and low of the company's common stock over the last 52 weeks?", "answer": "The intra-day trading high was $299.29 per share and the low was $152.37 per share."}
{"type": "financial", "level": "location", "length": "128k", "file": "Tesla, Inc..txt", "context_order": 4, "question": "What was the automotive sales revenue for the year ended December 31, 2023?", "answer": "$78,509 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Tesla, Inc..txt", "context_order": 5, "question": "What was Tesla, Inc.'s total revenue for the year ended December 31, 2023?", "answer": "$96,773 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Tesla, Inc..txt", "context_order": 6, "question": "What was the total cash and cash equivalents and restricted cash as of December 31, 2023?", "answer": "$17,189 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Tesla, Inc..txt", "context_order": 7, "question": "What was the carrying value of digital assets, net, as of December 31, 2023?", "answer": "$184 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Tesla, Inc..txt", "context_order": 8, "question": "What was Tesla's total revenue for the year ended December 31, 2023?", "answer": "$96,773 million."}
{"type": "financial", "level": "location", "length": "128k", "file": "Tesla, Inc..txt", "context_order": 9, "question": "Which independent registered public accounting firm audited the effectiveness of internal control over financial reporting as of December 31, 2023?", "answer": "PricewaterhouseCoopers LLP."}